×
About Michael B. Chancellor, M.D.
Dr. Chancellor has written over 550 peer-reviewed articles and book chapters in journals including The Journal of Urology, Urology, Gene Therapy, and Lancet. He has also written 11 books and serves on the editorial board of 12 scientific journals. A prolific author and researcher, Dr. Chancellor has gained national and international recognition in the areas of stem cell and tissue engineering as well as drug discovery. He was the first urologist to use botulinum toxin to treat lower urinary tract dysfunction. His inventions founded Cook MyoSite, Inc., which is now conducting multicenter North American trials using adult autologous muscle-derived stem cells to treat stress urinary incontinence. Dr. Chancellor also founded Lipella Pharmaceuticals, Inc., a biopharmaceutical company focusing on localized therapy and advance drug delivery.
2014 - Present | Director, The Robert B. and Ann S. Aikens Center for Neurology Research | |
|
||
2009 - Present | Professor, Oakland University William Beaumont School of Medicine ‐ Department of Urology | |
|
||
2008 - Present | Director of Neurourology Program, Beaumont ‐ Department of Urology | |
|
Disciplines
Research Interests
1989 - 1990 | Fellowship, College of Physicians and Surgeons, Columbia University ‐ Neuro-Urology | |
|
||
1985 - 1988 | Resident, Urology, University of Michigan Medical Center | |
|
||
1984 - 1985 | Resident, Surgery, University of Michigan Medical Center | |
|
||
1983 - 1984 | Intern, Surgery, University of Michigan Medical Center | |
|
||
1979 - 1983 | M.D., Medical College of Wisconsin | |
|
||
1976 - 1979 | B.S., University of Michigan - Ann Arbor ‐ Biology | |
|
Contact Information
3535 West 13 Mile Road
Medical Office Building,
Suite 404
Royal Oak, MI 48073
248-551-3535